Elan / Praveen
I think for the institutions etc their fiscal year ends in October. Plus the stock has such collosal volume, I don't think tax-selling would make a damn bit of difference.
"Biogen says there will be an FDA panel on Tysabri in March."
Is this per the Bloomberg link I sent you, or you have other information ?
"The FDA Advisory Panel on Peripheral and Central Nervous System Drugs meets March 7 and 8."
That has been scheduled for a while, and yet the companies were not "informed". I don't know why the FDA would a) wait so long as to have it in March; b) even if so, wait so long to tell them.
Market Data 
Markets 
AI
